Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM33 | Q9BZ11 | 9/20 | 0.84 |
| ▸ | ADAM17 | P78536 | 9/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998468 | 1.00 | ADAM33 (0.84) | ADAM33ADAM17MMP3MMP1HRH3 | |
| SCHEMBL998762 | 0.92 | ADAM33 (1.00) | ADAM33ADAM17MMP3MMP1ADAM9 | |
| SCHEMBL998761 | 0.92 | ADAM33 (1.00) | ADAM33ADAM17MMP3MMP1ADAM9 | |
| SCHEMBL2680985 | 0.92 | ADAM33 (0.80) | ADAM33ADAM17MMP3MMP1HRH3 | |
| SCHEMBL2680987 | 0.92 | ADAM33 (0.80) | ADAM33ADAM17MMP3MMP1HRH3 | |
| SCHEMBL998692 | 0.88 | ADAM33 (0.84) | ADAM33ADAM17MMP3MMP1BCL2L1 | |
| SCHEMBL998694 | 0.88 | ADAM33 (0.84) | ADAM33ADAM17MMP3MMP1BCL2L1 | |
| SCHEMBL998393 | 0.87 | ADAM33 (0.83) | ADAM33ADAM17MMP3MMP1 | |
| SCHEMBL998390 | 0.87 | ADAM33 (0.83) | ADAM33ADAM17MMP3MMP1 | |
| SCHEMBL996219 | 0.86 | ADAM33 (0.84) | ADAM33ADAM17MMP3MMP1ADAM9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448931-B1 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine | GALDERMA RES & DEV (FR) | 2015-05-27 | — | — | EP | disclosed |
| US-8772478-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-08 | — | — | US | disclosed |
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2448931-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | Galderma Research & Development (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001088-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, STS | ADAM33 3905/4885ADAM17 3458/4885MMP3 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.